Table 1.

Univariate and multivariate analysis of clinicopathological characteristics associated with overall survival and relapse-free survival

Univariate and multivariate analysis of clinicopathological characteristics associated with OSa
	Univariate			Multivariate
	HRb	95% CIc	p value	HR	95% CI	p value
Age (≥65/< 65)	3.331	1.319–8.411	0.011	4.37	1.461–13.072	0.008
Gender (female/male)	0.642	0.275–1.501	0.307
Location (rectum/colon)	0.405	0.161–1.020	0.055	0.250	0.082–0.764	0.015
Depth (T4/Tis, T1, T2, T3)	2.34	0.799–6.851	0.121	1.875	0.493–7.122	0.356
Lymph node metastasis (positive/negative)	2.649	1.186–5.917	0.018	1.544	0.608–3.923	0.361
Histological type (por, sig, muc/tub1, tub2)	3.204	1.093–9.396	0.034	7.830	2.000–30.651	0.003
Lymphatic duct invasion (positive/negative)	3.173	0.946–10.644	0.062	1.398	0.334–5.857	0.646
Venous invasion (positive/negative)	2.666	1.195–5.944	0.017	1.971	0.763–5.094	0.161
MAF expression (weak/strong)	2.934	1.002–8.585	0.049	3.084	0.921–10.320	0.068

Univariate and multivariate analysis of clinicopathological characteristics associated with RFSd
	Univariate			Multivariate
	HR	95% CI	p value	HR	95% CI	p value
Age (≥65/< 65)	6.355	1.878–21.502	0.003	10.464	2.693–40.659	<0.001
Gender (female/male)	0.795	0.333–1.895	0.604
Location (rectum/colon)	0.510	0.208–1.251	0.141	0.432	0.165–1.133	0.088
Depth (T4/Tis, T1, T2, T3)e	4.081	1.502–11.092	0.006	6.388	1.570–25.989	0.010
Lymph node metastasis (positive/negative)	2.787	1.207–6.436	0.016	1.853	0.648–5.299	0.250
Histological type (por, sig, muc/tub1, tub2)f	1.441	0.336–6.177	0.623
Lymphatic duct invasion (positive/negative)	2.544	0.861–7.520	0.091	1.124	0.286–4.416	0.867
Venous invasion (positive/negative)	2.697	1.163–6.253	0.021	1.341	0.444–4.051	0.602
MAF expression (weak/strong)	2.945	0.996–8.706	0.051	3.935	1.038–14.919	0.044

A Cox proportional hazard regression model was used to estimate HRs and 95% CIs. p values <0.05 were considered to indicate statistical significance.

^aOS, overall survival.

^bHR, hazard ratio.

^cCI, confidence interval.

^dRFS, relapse-free survival.

^eTis, carcinoma in situ; T1, involvement of submucosa; T2, involvement of muscularis propria; T3, involvement of subserosa; T4, involvement of serosal surface or direct invasion to other organs.

^ftub1, well differentiated adenocarcinoma; tub2, moderately differentiated adenocarcinoma; muc, mucinous carcinoma; por, poorly differentiated adenocarcinoma.